Table 3.
Prevalence of neural autoantibodies in serum and CSF of individuals with CHR states or schizophrenia and healthy controls.
| Titers (serum/CSF) | HV (serum/CSF) | CHR state (serum/CSF) | FEP (serum/CSF) | |
|---|---|---|---|---|
| N | 40/40 | 47/47 | 103/103 | |
| NMDAR (NR1 subunit) | 1:640a/– | 0/0 | 0/0 | 1 (0.97%)a/0 |
| GAD65 | –/– | 0/0 | 0/0 | 0/0 |
| LGI1 | –/– | 0/0 | 0/0 | 0/0 |
| CASPR2 | 1:20–1:160b/ – | 0/0 | 0/0 | 2b (1.94%)/0 |
| AMPAR subunit 1 | –/– | 0/0 | 0/0 | 0/0 |
| AMPAR subunit 2 | –/– | 0/0 | 0/0 | 0/0 |
| GABABR | –/– | 0/0 | 0/0 | 0/0 |
| Glycine receptors | –/– | 0/0 | 0/0 | 0/0 |
a
non-IgG antibodies.
b
IgG antibodies.
AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; CASPR2, contactin-associated protein-like 2; CSF, cerebrospinal fluid; GABABR, γ-aminobutyric acid-B receptors; GAD65, glutamic acid decarboxylase 65 kDa; LGI1, leucine-rich glioma inactivated protein 1; NMDAR, N-methyl-D-aspartate receptor.